We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expert Panel Shoots Down Chronic Kidney Disease Drug
FDA Expert Panel Shoots Down Chronic Kidney Disease Drug
An FDA advisory committee unanimously rejected recommending approval of Reata Pharmaceuticals’ bardoxolone methyl as a treatment for patients 12 years and up with chronic kidney disease caused by Alport syndrome (AS), a rare genetic disorder.